

Market Round-up

V16 – 7th September, 2018

General Market News:

- **Shire** announced that it has completed the sale of its Oncology franchise to **Servier** for \$2.4 billion. [READ](#)
- **AstraZeneca's** experimental drug **anifrolumab** has failed to hit targets in a late stage trial in patients with lupus. [READ](#)
- **Shire** could start to reclaim HAE Prophylaxis market from **CSL Behring** following FDA approval of **Takhzyro**. [READ](#)
- UK Hospitals are gearing up to offer **Novartis'** CAR-T therapy **Kymriah** to after a deal was reach with **NHS England**. The commercial deal with Novartis is the first in Europe, and comes less than 10 days after Kymriah won marketing authorisation, marking one of the *fastest funding approvals* in the NHS 70-year history. [READ](#)
- **JW Pharmaceutical** signs \$402m dermatology drug deal with **LEO Pharma**. [READ](#)
- **Chanelle** have announced an €86 million investment plan that will see the creation of 350 jobs in Galway over the next five years. [READ](#)
- **Novartis** is selling parts of its generics business **Sandoz** to **Aurobindo** in a deal worth at least \$900 million. [READ](#)
- **LEO Pharma** closes acquisition of Bayer's prescription dermatology business in the US. [READ](#)
- **Shire** buys Swiss plasma firm **sanaplasma** for undisclosed sum. [READ](#)
- **GSK** restructuring to result in 650 job cuts in the US. [READ](#)

Biosimilars:

- The FDA has granted a priority review to a supplemental biologics license application for **MSD's pembroliumab (Keytruda)**. [READ](#)
- **Celltrion Healthcare** is calling on the **NHS** to consider lowering the threshold for starting biologics in patients with rheumatoid arthritis (RA), and to put in place measures to boost patient access to such treatment. [READ](#)
- Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes published March 2018. [READ](#).

NCPE Drug Updates

- The guidelines for the inclusion of drug costs in economic evaluations have been revised and updated by the NCPE. [READ](#).

Drug Approvals:

- The HSE has recommended the use of **Bristol-Myers Squibb's** potentially life-extending cancer drug **nivolumab (Opdivo)** for patients with advanced lung cancer. [READ](#)
- EU approval was given to **Janssen** for **Darzalex** for the first-line treatment of patients with multiple myeloma. [READ](#)
- The European Commission has authorised **Sanofi's Cablivi (caplacizumab)** indicated for the treatment of adults experiencing an episode of Attp. [READ](#)
- The European Commission has approved **GSK's Nucala** has been approved for use in paediatric patients with severe eosinophilic asthma. [READ](#)
- The FDA approves **MSD's Delstrigo** and **Pifeltro** for HIV treatment. [READ](#)
- The FDA are undertaking a priority review for **MSD's Keytruda** for Merkel cell carcinoma. [READ](#)
- The FDA has granted breakthrough therapy designation to **Pfizer's** investigational **oral Janus kinase 3 (JAK3)** inhibitor PF-06651600 for the treatment of patients with alopecia areata. [READ](#)
-

Brexit:

- The Brexit uncertainty continues with **Pfizer** stating its costs for dealing with the upcoming split will reach \$100 million. [READ](#)

Further Reading:

- Global anti-counterfeit pharmaceutical packaging market is expected to be worth over \$1800.3 million by 2024. [READ](#)
- Delegates at the 2018 **International Pharmaceutical Federation conference** have been told that pharmacists working in UK GP practices are already making a positive difference for patients. [READ](#)
- **Amazon** is trying to tap into the \$300 billion market for online pharmacies — here's how it could change the healthcare industry. [READ](#)
- 90 Studies prove biosimilars' safety and efficacy: What Now? [READ](#)